Overexpression of mutant EGFR protein indicates a better survival benefit from EGFR-TKI therapy in non-small cell lung cancer

BACKGROUND: Epidermal growth factor receptor (EGFR) is a novel target for therapy in a subset of non-small cell lung cancer (NSCLC). Tumors with EGFR mutations showed good response to EGFR tyrosine kinase inhibitors (TKIs). We aimed to identify the discriminating capacity of immunohistochemistry (IH...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Ling, Yun, Yang, Xin, Li, Wenbin, Li, Zhuo, Yang, Lin, Qiu, Tian, Guo, Lei, Dong, Lin, Li, Lin, Ying, Jianming, Lin, Dongmei
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2016
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5288154/
https://ncbi.nlm.nih.gov/pubmed/27418143
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.10594
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados